Navigation Links
Surgistat II Electrosurgical Generator.

ProductsSurgistat II Electrosurgical Generator.
Company Valleylab
Item Surgistat II Electrosurgical Generator.
Features Easy and quick to set up; compact and light. Saves time with automatic access to previously used power settings and modes. Provides precise surgical effect with power control dials. Performs most common office-based electrosurgical procedures. Provides ability to change power settings while activating the generator. Accepts preferred accessories. Manufactured to the highest standards of quality in electrosurgical technology. Increased patient safety with a return electrode contact quality monitoring system (RECQMS).
Description Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit.
Info Valleylab
Customer Service: (800) 255-8522
Web site: http://www.valleylab.com/

Related medicine products :

1. Surgistat Electrosurgical Generator
2. Force EZ Electrosurgical Generator
3. Force FX Electrosurgical Generator
4. IDS-300 Electrosurgical Generator
5. IDS-200 Electrosurgical Generator
6. Finesse Electrosurgical Generator (100-120 VAC)
7. Finesse Electrosurgical Generator (200-240 VAC)
8. Finesse II Electrosurgical Generator (100-120 VAC)
9. Finesse II Electrosurgical Generator (200-240 VAC)
10. PenAdapt - Electrosurgical Pencil Adapter For The Collection Of Smoke Plume
11. Mega Power Electrosurgical Generator
Other Medicine News:Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 2Health News:ATS Medical Appoints James L. Cox, M.D. as Medical Director 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 4Health News:Blue Cross of California Gives $30,000 in Holiday Donations to Food Banks Throughout the State 2Health News:Panacea Pharmaceuticals Initiates GMP Manufacturing of Prostate Cancer Diagnostic Test Kits 2Health News:Panacea Pharmaceuticals Initiates GMP Manufacturing of Prostate Cancer Diagnostic Test Kits 3Health News:Panacea Pharmaceuticals Initiates GMP Manufacturing of Prostate Cancer Diagnostic Test Kits 4Health News:Rand study examines the effect of policy on entrepreneurship and small businesses 2Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 2Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 3Health News:Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee 4
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Exponent Reports Second Quarter 2009 Results 52462 1Exponent Reports Second Quarter 2009 Results 52462 2Exponent Reports Second Quarter 2009 Results 52462 3Exponent Reports Second Quarter 2009 Results 52462 4Exponent Reports Second Quarter 2009 Results 52462 5Exponent Reports Second Quarter 2009 Results 52462 6Exponent Reports Second Quarter 2009 Results 52462 7Exponent Reports Second Quarter 2009 Results 52462 8Exponent Reports Second Quarter 2009 Results 52462 9Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 1Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 2Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 3Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 4Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 1Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 2Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 3Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 4Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 6Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 7Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 8Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 9Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 10Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 11Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 12Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 13Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 14Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 15Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 16Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 17